Danielsen E R, Elberling T V, Rasmussen A K, Dock J, Hørding M, Perrild H, Waldemar G, Feldt-Rasmussen U, Thomsen C
Department of Radiology, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
J Clin Endocrinol Metab. 2008 Aug;93(8):3192-8. doi: 10.1210/jc.2007-2161. Epub 2008 May 20.
Graves' disease is an autoimmune disease of the thyroid gland. Patients often have affective and cognitive complaints, whether these disappear after treatment remains disputed.
Our objective was to evaluate cerebral biochemistry in acute and treated Graves' disease.
We conducted a prospective study, investigating volunteers once and patients before and 1 yr after treatment.
The study was performed at a radiology department, a memory disorder clinic, and two endocrinology clinics.
Of 53 consecutively referred, newly diagnosed, and untreated patients with Graves' thyrotoxicosis, 27 patients (34 +/- 8 yr) and 33 matched volunteers were included.
Patients were treated with thionamide.
We assessed brain metabolite concentrations.
Proton magnetic resonance spectroscopy of the brain and a battery of biochemical, affective, and cognitive tests were used.
Previously reported findings of reduced choline and myo-inositol in acute Graves' disease were confirmed and reversibility was demonstrated. Parieto-occipital white matter glutamine was and remained significantly reduced (P < 0.01). Acute phase parieto-occipital white matter total choline correlated significantly (r = -0.57; P < 0.01) with impaired thyroid function. Pretreatment total T(3) predicted posttreatment occipital gray matter glutamine (r = -0.52; P < 0.01). Occipital gray matter total choline (r = -0.53; P < 0.01) and parietooccipital white matter glutamate (r = -0.54; P < 0.01) correlated with initial values of selected attention and concentration cognitive scores and predicted them at follow-up.
The persistent reduction of glutamine in white matter, the decreasing glutamate in occipital gray matter, and the correlation with severity of the initial disease as well as with attention and concentration cognitive scores indicated that there was a persistent and possibly progressive disturbance of the glutamate glutamine cycling in Graves' disease.
格雷夫斯病是一种甲状腺自身免疫性疾病。患者常伴有情感和认知方面的不适,这些症状在治疗后是否消失仍存在争议。
我们的目的是评估急性和经治疗的格雷夫斯病患者的脑生化情况。
我们进行了一项前瞻性研究,对志愿者进行一次检查,对患者在治疗前和治疗后1年进行检查。
该研究在一个放射科、一个记忆障碍诊所和两个内分泌诊所进行。
在53例连续转诊、新诊断且未治疗的格雷夫斯甲状腺毒症患者中,纳入了27例患者(年龄34±8岁)和33例匹配的志愿者。
患者接受硫代酰胺治疗。
我们评估了脑代谢物浓度。
采用脑质子磁共振波谱以及一系列生化、情感和认知测试。
先前报道的急性格雷夫斯病中胆碱和肌醇减少的发现得到证实,并证明了其可逆性。顶枕白质谷氨酰胺含量持续显著降低(P<0.01)。急性期顶枕白质总胆碱与甲状腺功能受损显著相关(r=-0.57;P<0.01)。治疗前总T3可预测治疗后枕叶灰质谷氨酰胺含量(r=-0.52;P<0.01)。枕叶灰质总胆碱(r=-0.53;P<0.01)和顶枕白质谷氨酸(r=-0.54;P<0.01)与所选注意力和注意力集中认知评分的初始值相关,并可在随访时对其进行预测。
白质中谷氨酰胺持续减少、枕叶灰质中谷氨酸含量降低,以及与初始疾病严重程度以及注意力和注意力集中认知评分的相关性表明,格雷夫斯病中谷氨酸-谷氨酰胺循环存在持续且可能进展性的紊乱。